No abstract available.
Lupus Coagulation Inhibitor*

No abstract available.
Lupus Coagulation Inhibitor*

OBJECTIVE: To explore the association between neruopsychiatric manifestations and auto-antibodies in patients with neruopsychiatric lupus. METHODS: 233 patients with systemic lupus erythematosus (SLE) who were admitted or visited Kangnam St. Mary's Hospital from January 1993 to March 1996 were included in this study. The medical records of this group were reviewed in detail according to a predefined protocol with special emphasis upon any neruopsychiatric manifestations of the illness. RESULTS: 1) Among patients with SLE, 45(20.1%) had neruopsychiatric manifestations during the course of the disease. 2) The positivity of anticardiolipin antibody and antiribosomal P antibody is more frequent in neruopsychiatric group than that of non-neruopsychiatric lupus(56.3% vs. 22.9%, 44.1% vs. 21.5%, respectively, p<0.05). 3) The frequency of anticardiolipin antibody and lupus anticoagulant is more frequent in thrombotic group than that of non-thrombotic group(69.2% vs. 26.3%, 50.0% vs. 12.1%, respectively, p<0.05). CONCLUSIONS: Our findings suggest that investigation of the autoantibodies such as anticardiolipin antibody, antiribosomal P antibody, and lupus anticoagulant may be useful for early detection and management of SLE patients who have neruopsychiatric manifestations.
Antibodies, Anticardiolipin ; Autoantibodies* ; Humans ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic ; Medical Records

OBJECTIVES: To assess the prevalence of autoantibodies in patients with endometriosis MATERIALS AND METHODS: The prevalence of autoantibodies were investigated in 93 patients with endometriosis diagnosed by laparoscopy or laparotomy. Autoantibodies, such as antithyroglobulin antibody, antimicrosomal antibody, antinuclear antibody (ANA), antiphospho -lipid antibody (APA), lupus anticoagulant (LAC), anti-dsDNA, and rheumatoid factor, were measured in sera of the subjects. The prevalence and distribution of autoantibodies were analyzed according to the stage of endometriosis. RESULTS: All seven autoantibodies were checked in 73 patients out of 93 patients. Autoantibodies were identified in 23 of 73 patients with endometriosis (31.5%). Antibodies detected were antithyroglobulin antibody (15.2%), ANA (12.0%), antimicrosomal antibody (8.7%), anti-dsDNA (5.4%), and rheumatoid factor (4.4%), APA (2.2%) and LAC (1.3%). The prevalence of autoantibodies did not differ by the AFS stage. CONCLUSION: Autoantibodies were detected in about one-third of patients with endometriosis. The prevalence of autoantibodies did not differ by the stage.
Antibodies ; Antibodies, Antinuclear ; Autoantibodies* ; Endometriosis* ; Female ; Humans ; Laparoscopy ; Laparotomy ; Lupus Coagulation Inhibitor ; Prevalence* ; Rheumatoid Factor

Sneddon's syndrome consists of widespread livedo reticularis and ischemic cerebral manifestations. We report a case of a 70-year-old Korean woman with extensive livedo reticularis, hypertension, positive laboratory results for antinuclear antibodies and the lupus anticoagulant test, and idiopathic Parkinson's disease.
Aged ; Antibodies, Antinuclear ; Female ; Humans ; Hypertension ; Livedo Reticularis ; Lupus Coagulation Inhibitor ; Parkinson Disease

The presence of a lupus anticoagulant was evaluated in patients with Bechet's disease by the kaolin clotting time method. Four percents (three patients) of 69 patients analyzed were found positive for the lupus anticoagulant. However, no statistically significant association existed between the presence of this antibody and the presence of thrombosis, clinical activity, clinical type, antinuclear antibodies and the positive VDRL test.
Behcet Syndrome/*immunology ; Cardiolipins/immunology ; Female ; Human ; Lupus Coagulation Inhibitor/*analysis ; Male

BACKGROUND: Although anticardiolipin antibody(aCL)-related stroke is far more frequently identified in younger populations, the role of aCL in the pathogenesis of cerebral infarction may be important also in the old, stroke-prone population. We studied the clinical profiles of aCL- related stroke in elderly patient to look at its role on the pathogenesis of ischemic stroke. METHODS: We analyzed unselected patients with acute ischemic stroke and age matched controls for the presence of aCL, prospectively. Also, we studied the characteristics of these patients based on the conventional risk factors and other clinical, laboratory and radiological features in them. RESULTS: aCL was positive 30 (14.7%) of 203 stroke patients, but 11 (6.1%) in 193 control patients. The proportion of patients having more than one of the risk factors was significantly greater in aCL-positive (24/30, 80.0%) than in aCL-negative patients (100/173, 57.8%). The incidence of aCL positivity was significantly greater in patients having one or more risk factors (24/124, 19.3%) than in patients not having any of the risks (6/79, 7.6%). Two of the patients had prolonged aPTT, and only one had a lupus anticoagulant. A positive ANA and false-positive VDRL were not found in our patients. Radiological findings confer subcortical infarction. CONCLUSION: The elevated aCL are a risk marker for stroke also in the elderly population. Our aCL-positive patients generally had multiple risk factors for stroke and are associated with subcortical infarctions, contrary to previous studies. The role of aCL as a disease marker for ischemic stroke in elderly patients warrants further investigations.
Aged* ; Antibodies, Anticardiolipin* ; Cerebral Infarction ; Humans ; Incidence ; Lupus Coagulation Inhibitor ; Prospective Studies ; Risk Factors ; Stroke*

The antiphospholipid syndrome is a multisystemic disorder comprising of venous and arterial thrombotic events, recurrent unexplained fetal losses, moderate thrombocytopenia, and a high frequency of neurologic events with laboratory findings of a positive lupus anticoagulant test or anticardiolipin antibody. It may occur in association with other disorders, particularly autoimmune diseases, in which case it is referred to as secondary antiphospholipid syndrome. But when it occurs without obvious underlying disease, it is primary antiphospholipid syndrome. We report a case of primary antiphospholipid syndrome in a 5 year old female child who had a cerebrovascular attack, moderate thrombocytopenia and splenomegaly.
Antibodies, Anticardiolipin ; Antiphospholipid Syndrome* ; Autoimmune Diseases ; Child* ; Child, Preschool ; Female ; Humans ; Lupus Coagulation Inhibitor ; Splenomegaly ; Thrombocytopenia

OBJECTIVE: Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is a special subtype of antiphospholipid syndrome (APS) characterized by multiple intravascular thrombosis involving multiple organs systems or tissues simultaneously or continuously, high titer antiphospholipid antibodies and high mortality rate. This article's aims was to analyze the clinical manifestation, laboratory examination and treatment therapy of CAPS for the purpose of improving the understanding, diagnosis and treatment of the disease in clinical practice. METHODS: Retrospective analysis and descriptive statistics were applied to the clinical manifestations and laboratory findings of 14 CAPS cases from APS Shanghai Database (APS-SH) with catastrophic antiphospholipid. RESULTS: Of the 14 CAPS patients, 12 cases satisfied the 2003 CAPS Classification Criteria accepted in the 10th International Congress on Antiphospholipid Antibody, and were diagnosed as definite APS and 2 cases were diagnosed as probable CAPS. Three cases were categorized as primary APS and 11 as APS secondary to systemic lupus erythematosus (SLE). Infection was mostly commonly seen before the onset of CAPS, followed by SLE activity and surgery. Among the involved organs, systems and tissues, brain and lung were most commonly affected sites of arterial thrombosis while peripheral vein was most commonly affected in venous thrombosis events among the clinical events. Triple positivity of anticardiolipin antibody (aCL), anti-β2 glyeoprotein I antibody (aβ2GPI), lupus anticoagulant (LA) were detected in 54.55% of the patients. Thrombocytopenia and decreased hemoglobin were frequently seen in the CAPS patients, and the majority proved to be hemolytic anemia. Of all the cases, 6 ended with death. The triple therapy strategy (anticoagulants, glucocorticoid, intravenous immunoglobulin and/or plasma exchange) could help to improve prognosis, cyclophosphamide and rituximab might benefit the patients with other comorbidities such as SLE and micro-angiopathic hemolytic anemia (MHA). CONCLUSION CAPS patients suffer from life-threatening acute multiple small vessel thrombosis with high titer of antiphospholipid antibody, potentially leading to multiple organ failure and a poor prognosis, thus early diagnosis and sufficient treatment are critical to prevent the progression of disease and improve the prognosis.
Antibodies, Antiphospholipid ; Antiphospholipid Syndrome/therapy* ; Catastrophic Illness ; Humans ; Lupus Coagulation Inhibitor ; Retrospective Studies ; Thrombosis/etiology*

Antiphospholipid antibody syndrome is recognized as one of the most important causes of hypercoagulability. Itcan be clinically diagnosed if patients have experienced unexplained recurrent venous or arterial thrombosis,recurrent fetal loss, or thrombocytopenia in the presence of circulating autoantibodies to phospholipids, such asanticardiolipin antibody or lupus anticoagulant. Approximately half of all patients with this syndrome do not haveassociated systemic disease, and their condition is described as primary antiphospholipid antibody syndrome(PAPS). In the remainder, the syndrome is accompanied by systemic lupus erythematosus or other connective tissuediseases, and is known as secondary antiphospholipid syndrome (1). The purpose of this paper is to illustrate thesystemic manifestations of PAPS, focusing on the radiological findings of CT, MR and angiography in clinicallyproven patients.
Angiography ; Antibodies, Antiphospholipid* ; Antiphospholipid Syndrome* ; Autoantibodies ; Humans ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic ; Phospholipids ; Thrombocytopenia ; Thrombophilia ; Thrombosis ; Venous Thrombosis